共查询到20条相似文献,搜索用时 16 毫秒
1.
Rumi Sato Nobuyuki Hamada Takahito Kashiwagi Yoshihiro Imamura Koyu Hara Munetsugu Nishimura Tomoko Kamimura Tomohiko Takasaki Hiroshi Watanabe Takeharu Koga 《Tropical Medicine and Health》2015,43(2):85-88
An adult Japanese man who had just returned from Thailand developed dengue hemorrhagic fever (DHF). A primary infection of dengue virus (DENV) was confirmed, specifically DENV serotype 2 (DENV-2), on the basis of the detection of the virus genome, a significant increase in the neutralizing antibody and the isolation of DENV-2. DHF is often observed following a secondary infection from another serotype of dengue virus, particularly in children, but this case was a primary infection of DENV. Japan is a non-endemic country for dengue disease. In fact, only Japanese encephalitis (JE) is known to be a member of the endemic flavivirus family. In this study, IgG antibody against Japanese encephalitis virus (JEV) was detected. JEV belongs to the family of dengue virus and prevails in Japan, particularly Kyushu. Among many risk factors for the occurrence of DHF, a plausible candidate could be a cross-reactive antibody-dependent enhancement (ADE) mechanism caused by JEV antibody. This indicates that most Japanese travelers who living in dengue non-endemic areas, particularly Kyushu, should be aware of the occurrence of DHF. 相似文献
2.
Annette Fox Stephen Whitehead Katherine L. Anders Le Nguyen Minh Hoa Le Quynh Mai Pham Quang Thai Nguyen Thu Yen Tran Nhu Duong Dang Dinh Thoang Jeremy Farrar Heiman Wertheim Cameron Simmons Nguyen Tran Hien Peter Horby 《The American journal of tropical medicine and hygiene》2014,90(5):892-896
This study investigated whether a large dengue epidemic that struck Hanoi in 2009 also affected a nearby semirural area. Seroconversion (dengue virus-reactive immunoglobulin G enzyme-linked immunosorbent assay) was high during 2009 compared with 2008, but neutralization assays showed that it was caused by both dengue virus and Japanese encephalitis virus infections. The findings highlight the importance of continued Japanese encephalitis virus vaccination and dengue surveillance.Dengue is an emerging health problem in northern Viet Nam, and in Hanoi, the capital, the largest recorded outbreak occurred in 2009, when 16,175 clinical cases were reported.1 Clinical dengue incidence in northern Viet Nam is highest in urban Hanoi, and transmission commences around July, several months after the end of winter, and ceases in late December,1 coinciding with changes in vector abundance.2 Dengue cases have been detected sporadically in other northern provinces of Viet Nam,3 and 11% of dengue patients presenting to a Hanoi hospital during 2008 had come from other provinces.4 The extent to which this finding reflects local transmission or infections acquired during travel to endemic areas, such as Hanoi, is not clear. Serology is an important tool for understanding dengue virus (DENV) transmission, because a variable and sometimes large proportion of infections can be asymptomatic.5 Therefore, we used serology to investigate DENV infection and transmission in a semirural commune approximately 60 km from Hanoi.A cohort of 270 households was selected randomly from a semirural commune in Hanam province. Blood samples were collected in December of 2007, December of 2008, June of 2009, and April of 20106 (i.e., outside the typical dengue season). The research was approved by the institutional review board of the National Institute of Hygiene and Epidemiology and the Oxford Tropical Research Ethics Committee, University of Oxford. All participants provided written informed consent. DENV-reactive immunoglobulin G (IgG) in sera was detected by indirect enzyme-linked immunosorbent assay (ELISA) using plates coated with purified DENV-1, -2, -3, and -4 virions (Panbio E-DEN01G; Alere, Brisbane, Australia). As per the manufacturer''s instructions, sera with absorbance values < 0.9 times the cutoff for the kit were classified as negative, sera with values > 1.1 times the cutoff were classified as positive, and sera with intermediate values were classified equivocal. ELISA seroconversion was defined as a change from negative to positive. Both Japanese encephalitis virus (JEV) and DENV circulate in northern Viet Nam, and there is substantial cross-reactivity between flavivirus antibodies.7,8 Therefore, a subset of sera was assessed using the plaque reduction neutralization test (PRNT) with DENV-1, -2, -3, and -4 and JEV antigens performed as described previously.9In total, 606 participants provided blood samples in April of 2010; 29 of those participants had equivocal DENV IgG ELISA results and were excluded. Of the remaining 577 participants, 240 (41.6%) participants were male, and the median age was 31 years (interquartile range [IQR] = 13–45); 205 (35.5%) participants were DENV IgG-seropositive, and 372 (64.5%) participants were seronegative. Seroprevalence increased with age (Figure 1), and seropositive participants were significantly older than seronegative participants (median = 49 years, IQR = 32–59 years versus median = 25 years, IQR = 13–40 years, P < 0.001). Earlier samples were assessed to determine the proportions that seroconverted during 2008 or 2009 or were already seropositive at baseline in 2007; 3 participants did not have an earlier serum sample, and 13 participants had equivocal results, leaving 561 participants who could be assessed for seroconversion. In total, 143 of 561 (25.5%) participants were already seropositive at baseline, and 418 participants were seronegative, of whom 3 (0.7%, 95% confidence interval [95% CI] = 0.1–2.2%) participants seroconverted during 2008 compared with 43 of 415 (10.4%, 95% CI = 7.6–14.0%) participants seroconverted during 2009. Participants who seroconverted during 2009 were significantly younger (median = 32 years, IQR = 17–47 years) than participants who were already seropositive (median = 54 years, IQR = 42–63 years, P < 0.001). However, the proportion of children ages 10 years or less who seroconverted was very low (Figure 1).Open in a separate windowFigure 1.DENV IgG seroprevalence and seroconversion according to age. Results are shown as the proportion of participants that were DENV IgG-seropositive in either December of 2007 (gray bars) or April of 2010 (white bars). Also shown is the proportion of participants who seroconverted during 2009 (seronegative in December of 2008 and seropositive by April of 2010; black bars). The numbers shown below the chart are the denominator for each age group (N) and the denominator for seroconversion (N*; i.e., the number in each age group that was seronegative at baseline).Virus neutralization assays were performed on paired sera from participants who seroconverted and had sufficient sera remaining (31/46). The median age of this subset of participants was 31 years (IQR = 17–47 years), similar to the age of all seroconverters. DENV-1 and JEV but not DENV-2, -3, or -4 reactive antibodies were detected in post-infection sera from seroconverters by PRNT assay when titers were based on a 70% reduction in plaques (Age (years) Sex Inference Dengue PRNT 70* PRNT 90* IgG ELISA† JEV DENV-1 JEV DENV-1 Pre Post Pre Post Ratio Pre Post Ratio Pre Post Pre Post 54 F DENV-1 0.58 3.29 26 29 1.1 – 151 30.2 14 11 – 87 31 F DENV-1 0.19 2.82 19 17 0.9 – 38 7.6 – 10 – 26 45 F DENV-1 0.29 2.43 14 35 2.5 – 30 6.0 – 15 – 19 16 M DENV-1 0.61 3.76 22 19 0.9 – 31 6.2 11 – – 14 12 M DENV-1 0.32 1.28 11 – 0.5 – 22 4.4 – – – 12 36 M DENV-1 or JEV 0.17 3.72 10 73 7.3 – 31 6.2 – 14 – 19 14 M JEV 0.24 2.34 – 1,053 210.6 – – – 339 – – 18 M JEV 0.26 1.80 13 126 9.7 – – – 70 – – 5 F JEV 0.37 1.52 – 114 22.8 – – – 52 – – 24 M JEV 0.69 1.60 29 64 2.2 – – 16 30 – – 12 F JEV 0.23 2.67 – 33 6.6 – – – 11 – – 49 M Possible JEV 0.38 1.28 45 90 2.0 – – 23 49 – – 40 M Possible JEV 0.55 1.16 32 70 2.2 – – 16 14 – – 35 F Possible JEV 0.64 1.75 38 50 1.3 – – 18 14 – – 46 F Possible JEV 0.68 1.24 64 101 1.6 – – 30 25 – – 15 F Possible JEV 0.11 1.41 – 12 2.4 – – – – – – 19 M Possible JEV 0.12 1.26 – 11 2.2 – – – – – – 19 F Possible JEV 0.30 1.54 20 34 1.7 – – 10 – – – 43 F False 0.10 2.50 – – – – – – – – 51 M False 0.14 4.35 37 12 0.3 – – 19 12 – – 19 F False 0.38 1.11 32 32 1.0 – – 16 19 – – 46 M False 0.50 1.17 38 16 0.4 – – 18 – – – 16 M False 0.75 1.33 36 20 0.6 – – 13 – – – 30 F False 0.76 1.51 15 13 0.9 – – – – – – 12 F False 0.80 1.63 34 30 0.9 – – 16 12 – – 26 F False 0.81 1.57 19 – 0.3 – – 11 – – – 41 M False 0.81 1.21 12 – 0.4 – – – – – – 54 F False 0.82 1.88 – – – – – – – – 43 F False 0.82 1.46 49 – 0.1 – – 17 – – – 17 F False 0.83 1.36 115 82 0.7 – – 38 36 – – 49 F False 0.90 1.24 59 26 0.4 – – 28 10 – –